Stockreport

Largest Published Study of Molecular Residual Disease (MRD) in Stage III Colon Cancer Shows Guardant Reveal Blood Test More Precisely Identifies Risk of Recurrence After Surgery to Support...

Guardant Health, Inc.  (GH) 
Last guardant health, inc. earnings: 2/24 04:03 pm Check Earnings Report
PDF Data published in Journal of Clinical Oncology supports routine use of circulating tumor DNA (ctDNA) testing in management of stage III colon cancer patients PALO ALT [Read more]